At its recent annual Science Day, Moderna signaled a profound strategic shift, moving beyond its foundational infectious disease vaccine and…
Read More
Moderna bets on mRNA’s second act with cancer, autoimmune programs and AI research platform
At its recent annual Science Day, biotechnology giant Moderna signaled a profound strategic expansion beyond its highly successful infectious disease…
Read More
Moderna bets on mRNA’s second act with cancer, autoimmune programs and AI research platform
Moderna, the biotechnology firm that gained global prominence for its mRNA-based COVID-19 vaccine, is embarking on a significant strategic pivot,…
Read More
Biogen Pauses or Terminates Investment in Most of Apellis’ Legacy Research Programs Following $5.6 Billion Acquisition
Three months after Biogen finalized its substantial $5.6 billion acquisition of Apellis Pharmaceuticals, a significant shift in research and development…
Read More
CGTxchange Launches to Revitalize Shelved Cell and Gene Therapy Programs
The American Society of Gene & Cell Therapy (ASCGT) and Orphan Therapeutics Accelerator (OTXL) have officially unveiled CGTxchange, an innovative,…
Read More
Daiichi Sankyo Partners with Waiv to Accelerate Digital Pathology Biomarker Discovery for Antibody-Drug Conjugate Programs
In a strategic move to enhance precision in oncology drug development, Japanese pharmaceutical giant Daiichi Sankyo has announced a significant…
Read MoreYOU MAY HAVE MISSED
